Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

59.70 -1.41 (-2.30%)
Streaming Delayed Price Updated: 11:32 AM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
88 89 Next >
News headline image
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
News headline image
3 High-Yield Dividend Stocks With Payout Ratios Below 75% ↗
Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses. 
Via The Motley Fool
News headline image
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever ↗
These underappreciated dividend payers offer yields above 4% at recent prices. 
Via The Motley Fool
Topics Stocks
News headline image
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on BMY Options ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
News headline image
Key Takeaways From Bristol-Myers Squibb Analyst Ratings ↗
 
Via Benzinga
News headline image
Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer ↗
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and... 
Via Benzinga
News headline image
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Check Out What Whales Are Doing With BMY ↗
 
Via Benzinga
News headline image
Smart Money Is Betting Big In BMY Options ↗
 
Via Benzinga
News headline image
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
News headline image
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade ↗
With yields above 4%, these stocks could do a lot to boost your passive income stream 
Via The Motley Fool
News headline image
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Smart Money Is Betting Big In BMY Options ↗
 
Via Benzinga
News headline image
Where Will Bristol Myers Squibb Be in 5 Years? ↗
The drugmaker will go through key changes by the end of the decade. 
Via The Motley Fool
News headline image
3 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗
ETFs offer a good way to own a diversified portfolio of income-producing equities. 
Via The Motley Fool
Topics ETFs
News headline image
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations ↗
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
News headline image
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' ↗
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
News headline image
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome ↗
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
News headline image
The 3 Best Healthcare Stocks to Buy in August 2024 ↗
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity. 
Via InvestorPlace
News headline image
Bristol-Myers Squibb Co: Is It A Buy? ↗
As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens:... 
Via Talk Markets
News headline image
3 Stocks Retirees Should Absolutely Love ↗
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
News headline image
3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
News headline image
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever. ↗
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 7/29 - 8/2
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move 
Via MarketBeat
Topics Economy Stocks
News headline image
The 3 Biggest Earnings Beats for Q2 as of August 1, 2024 ↗
The stocks serving up the biggest earnings beats may just go on to offer investors fabulous returns going forward. 
Via InvestorPlace
Topics Earnings
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.